Shares of Shilpa Medicare Ltd were trading in the green and 4% higher on 5 May after the company’s Dharwad plant gained EU GMP clearance.

The company’s biologics business, Shilpa Biologics, in Dharwad, Karnataka, has gained European GMP accreditation for producing test batches following an inspection conducted by Austria’s competent body between 18 and 20 February 2025.

The authority of Austria concluded the inspection with zero observations.

The inspection, which included the sterile drug product filling and packaging line, quality systems, and quality control laboratories, found compliance with Good Manufacturing Practice principles and recommendations.

Shilpa Biologicals, the company’s subsidiary, signed a binding term sheet with Switzerland-based mAbTree Biologics AG in March to develop, manufacture, market, and sell a new biological entity (NBE).

On 18 September 2024 and 4 June 2024, the share reached a 52-week high of Rs 959.95 and a 52-week low of Rs 419.10.

At 12:08 pm, the shares of Shilpa Medicare were trading 4.48% higher at Rs 658.70 on NSE.

Curious About Shilpa Medicare Ltd? Ask the Analyst.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!